US FDA submissions pit Novartis and Kite head-to-head in CAR race
Novartis Gains Access to Celyad's allogenic CAR-T cell patents
Novartis launches 'next-generation' CAR-T platform
Novartis CAR-T cancer therapy wins expert support for FDA approval - STAT
The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis'
CAR-T Cell Therapy: Learnings From HCPs | Knowledge | CREATION.co
The Process of CAR-T Cell Therapy | Novartis
CAR T-Cell Therapies Current Limitations Future Opportunities
Historical moment! Milestone in immunotherapy: the world's first CAR-T cell product, CTL019, is approved for sale - Yongtai
Oxford BioMedica signs $100m CAR-T deal with Novartis | pharmaphorum
CAR-T Healthcare Professionals | Novartis
CAR-T cell therapy | Our works | Digital agency buckle up
Fraunhofer IZI and Novartis Continue Successful Collaboration with CAR-T Cell Therapy - Fraunhofer IZI
Chimeric Antigen Receptor T Cell (CAR T) Therapy | Novartis
Novartis fills manufacturing gap for CAR-T therapy Kymriah with first Asian production facility | Fierce Pharma
UK approves Novartis CAR-T therapy for children with blood cancer | S&P Global Market Intelligence
Primary analysis results from Novartis pivotal JULIET trial show Kymriah™
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice - IndiaMedToday
NHS to fund Novartis' CAR-T therapy Kymriah | pharmaphorum
CAR-T: Novartis prices CTL019 at US$475,000 - European Biotechnology
Global Manufacturing of CAR T Cell Therapy: Molecular Therapy - Methods & Clinical Development
Building blocks for institutional preparation of CTL019 delivery - Cytotherapy
Anvisa aprova produto de terapia avançada para tratamento de câncer - ISMEP - Instituto Santa Marta de Ensino e Pesquisa
FDA Approves Novartis CAR-T Cancer Treatment First Gene Therapy
CAR-Ts: Novartis wins UK - European Biotechnology
CAR-T Cell Therapy Clinical Trials
University of Pennsylvania Announces Completion of Exclusive R&D Alliance With Novartis and Development of New Focused Relationship - Penn Medicine
